Patient characteristics; n = 60
Median age, y (range) | 61 (50-74) |
| Diagnosis, no. (%) | |
| AML* | 54 (90) |
| RAEB-2/CMML-2 | 6 (10) |
| Secondary AML/MDS, no. (%) | |
| Prior MDS | 18 (30) |
| Other malignancy† | 11 (18) |
| Karyotype, no. (%) | |
| Diploid | 30 (50) |
| Abnormal | 30 (50) |
| −5/−7 | 15 (25) |
| +8 | 10 (16) |
| del(11)(q23) | 3 (5) |
| FLT3 abnormalities, no. (%) | |
| ITD, D835 | 11 (21) |
| Not assessed | 7 (12) |
Median age, y (range) | 61 (50-74) |
| Diagnosis, no. (%) | |
| AML* | 54 (90) |
| RAEB-2/CMML-2 | 6 (10) |
| Secondary AML/MDS, no. (%) | |
| Prior MDS | 18 (30) |
| Other malignancy† | 11 (18) |
| Karyotype, no. (%) | |
| Diploid | 30 (50) |
| Abnormal | 30 (50) |
| −5/−7 | 15 (25) |
| +8 | 10 (16) |
| del(11)(q23) | 3 (5) |
| FLT3 abnormalities, no. (%) | |
| ITD, D835 | 11 (21) |
| Not assessed | 7 (12) |
RAEB-2 indicates refractory anemia with excess blasts-2 (more than 10%); D835, FLT3 mutation of aspartate residue 835 of tyrosine kinase loop.
Distribution by French-American-British (FAB) classification: MO (2 patients), M1 (2), M2 (4), M4 (8), M5 (4), M6 (2), not available (32)
Includes breast cancer (3 patients), non-Hodgkin lymphoma (3), chronic myeloproliferative disorder (2), multiple myeloma (1), ALL (1), and chronic lymphocytic leukemia (1).